KEYNOTE-189: Chemo + Immunotherapy Now Viable for PD-L1 Low NSCLC KEYNOTE-189: Chemo + Immunotherapy Now Viable for PD-L1 Low NSCLC

While KEYNOTE-189 answered many questions about immuno-oncology for NSCLC, Drs West and Borghaei look forward to results of KEYNOTE-042 for even more answers.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news